Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ABBVNASDAQ:ALECNASDAQ:AMLXNASDAQ:ATHANASDAQ:COYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABBVAbbVie$186.58-7.5%$200.61$153.58▼$218.66$330.06B0.615.78 million shs13.50 million shsALECAlector$1.02-6.4%$1.53$1.01▼$6.78$101.07M0.73779,337 shs821,005 shsAMLXAmylyx Pharmaceuticals$3.43-2.3%$3.55$1.58▼$7.27$303.91M-0.531.35 million shs914,194 shsATHAAthira Pharma$0.25-3.8%$0.40$0.25▼$3.67$9.76M3.051.48 million shs201,756 shsCOYACoya Therapeutics$5.45-10.7%$6.48$4.75▼$10.24$91.15M0.3170,337 shs126,493 shs20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABBVAbbVie-7.32%-9.04%-11.83%+2.96%+5.21%ALECAlector-6.42%-20.93%-34.19%-50.49%-82.68%AMLXAmylyx Pharmaceuticals-2.28%-6.28%+2.08%-17.35%+30.42%ATHAAthira Pharma-3.85%-18.03%-34.07%-56.37%-90.00%COYACoya Therapeutics-10.66%-16.92%-16.41%-10.80%-45.01%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABBVAbbVie4.6881 of 5 stars3.53.03.33.93.42.51.3ALECAlector3.6351 of 5 stars3.12.00.04.52.51.70.6AMLXAmylyx Pharmaceuticals2.5787 of 5 stars3.41.00.00.01.84.21.3ATHAAthira Pharma1.4038 of 5 stars3.02.00.00.00.01.71.3COYACoya Therapeutics1.8813 of 5 stars3.53.00.00.02.80.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABBVAbbVie 2.92Moderate Buy$211.4513.33% UpsideALECAlector 2.14Hold$3.50243.14% UpsideAMLXAmylyx Pharmaceuticals 2.71Moderate Buy$7.33113.80% UpsideATHAAthira Pharma 2.00Hold$13.835,433.33% UpsideCOYACoya Therapeutics 3.00Buy$17.00211.93% UpsideCurrent Analyst Ratings BreakdownLatest AMLX, ALEC, ABBV, ATHA, and COYA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/20/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.003/18/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/17/2025ABBVAbbVieErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/10/2025COYACoya TherapeuticsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/7/2025ALECAlectorMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingUnderweight$3.00 ➝ $1.503/5/2025ABBVAbbVieWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$210.00 ➝ $240.003/5/2025AMLXAmylyx PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.003/4/2025ABBVAbbVieBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$200.00 ➝ $223.002/27/2025ALECAlectorHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $7.002/6/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.00(Data available from 4/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABBVAbbVie$56.33B5.86$13.79 per share13.53$1.90 per share98.20ALECAlector$100.56M1.01N/AN/A$1.41 per share0.72AMLXAmylyx Pharmaceuticals$87.37M3.48$0.62 per share5.51$6.42 per share0.53ATHAAthira PharmaN/AN/AN/AN/A$3.42 per shareN/ACOYACoya Therapeutics$3.55M25.65N/AN/A$2.47 per share2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABBVAbbVie$4.28B$2.4077.7413.351.627.59%296.28%12.65%4/25/2025 (Estimated)ALECAlector-$130.39M-$1.23N/AN/AN/A-257.54%-108.77%-27.03%5/6/2025 (Estimated)AMLXAmylyx Pharmaceuticals$49.27M-$4.44N/AN/AN/AN/A-36.97%-29.61%5/8/2025 (Estimated)ATHAAthira Pharma-$117.67M-$2.53N/AN/AN/AN/A-115.62%-88.94%5/13/2025 (Estimated)COYACoya Therapeutics-$7.99M-$0.98N/AN/AN/AN/A-31.63%-27.76%5/8/2025 (Estimated)Latest AMLX, ALEC, ABBV, ATHA, and COYA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/25/2025N/AABBVAbbVie$2.51N/AN/AN/A$12.91 billionN/A3/18/2025Q4 2024COYACoya Therapeutics-$0.32-$0.18+$0.14-$0.18$0.10 million$0.20 million3/4/2025Q4 2024AMLXAmylyx Pharmaceuticals-$0.49-$0.55-$0.06-$0.55N/A($0.67) million2/27/2025Q4 2024ATHAAthira Pharma-$0.45-$0.39+$0.06-$0.39N/AN/A2/26/2025Q4 2024ALECAlector-$0.61-$0.02+$0.59-$0.02$20.41 million$54.24 million1/31/2025Q4 24ABBVAbbVie$2.98$2.16-$0.82-$0.02$14.81 billionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABBVAbbVie$6.563.52%+6.04%273.33%53 YearsALECAlectorN/AN/AN/AN/AN/AAMLXAmylyx Pharmaceuticals$1.0229.62%N/AN/A N/AATHAAthira PharmaN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ALatest AMLX, ALEC, ABBV, ATHA, and COYA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/13/2025ABBVAbbViequarterly$1.643.4%4/15/20254/15/20255/15/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABBVAbbVie17.940.660.55ALECAlectorN/A3.293.29AMLXAmylyx PharmaceuticalsN/A4.554.55ATHAAthira PharmaN/A2.952.95COYACoya TherapeuticsN/A15.3115.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABBVAbbVie70.23%ALECAlector85.83%AMLXAmylyx Pharmaceuticals95.84%ATHAAthira Pharma57.12%COYACoya Therapeutics39.75%Insider OwnershipCompanyInsider OwnershipABBVAbbVie0.08%ALECAlector9.10%AMLXAmylyx Pharmaceuticals11.70%ATHAAthira Pharma19.80%COYACoya Therapeutics12.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABBVAbbVie50,0001.77 billion1.76 billionOptionableALECAlector27099.09 million89.02 millionOptionableAMLXAmylyx Pharmaceuticals20088.60 million60.53 millionOptionableATHAAthira Pharma4039.04 million31.01 millionOptionableCOYACoya Therapeutics616.73 million14.70 millionNot OptionableAMLX, ALEC, ABBV, ATHA, and COYA HeadlinesRecent News About These CompaniesAIGH Capital Management LLC Grows Holdings in Coya Therapeutics, Inc. (NASDAQ:COYA)March 31, 2025 | marketbeat.comCoya Therapeutics' (COYA) Buy Rating Reiterated at D. Boral CapitalMarch 30, 2025 | americanbankingnews.comChardan Capital Has Strong Estimate for COYA FY2025 EarningsMarch 29, 2025 | americanbankingnews.comCoya Therapeutics (NASDAQ:COYA) Given "Buy" Rating at D. Boral CapitalMarch 28, 2025 | marketbeat.comChardan Capital Has Strong Forecast for COYA FY2025 EarningsMarch 28, 2025 | marketbeat.comWhat Makes Coya Therapeutics, Inc. (COYA) a New Buy StockMarch 27, 2025 | zacks.comWall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a BetMarch 27, 2025 | zacks.comCoya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome ProgramMarch 26, 2025 | businesswire.comCoya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from Chardan CapitalMarch 21, 2025 | marketbeat.comCoya Therapeutics Reports 2024 Financial Results and ProgressMarch 21, 2025 | tipranks.comCoya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth PlansMarch 20, 2025 | finance.yahoo.comCoya Therapeutics (NASDAQ:COYA) Releases Quarterly Earnings Results, Beats Estimates By $0.14 EPSMarch 19, 2025 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral CapitalMarch 19, 2025 | marketbeat.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial ResultsMarch 18, 2025 | finance.yahoo.comCoya Therapeutics Reports 2024 Financial Results and UpdatesMarch 18, 2025 | tipranks.comCoya Therapeutics (COYA) to Release Earnings on TuesdayMarch 11, 2025 | marketbeat.comD. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA)March 10, 2025 | marketbeat.comCoya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and CombinationsFebruary 26, 2025 | businesswire.comCoya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and CombinationsFebruary 25, 2025 | businesswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Medtronic (MDT), Biohaven Ltd. (BHVN) and Arvinas Holding Company (ARVN)February 12, 2025 | markets.businessinsider.comCoya Therapeutics Now Pivots Toward Phase 2 In ALS And FTDFebruary 7, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBy Chris Markoch | March 23, 2025View AbbVie Stock Boosts Portfolios With Entry Into Weight Loss MarketBerkshire Hathaway Gains Defy Stock Market Slump By Jeffrey Neal Johnson | April 1, 2025View Berkshire Hathaway Gains Defy Stock Market Slump Berkshire Hathaway Bets on Constellation Brands—Should You?By Sarah Horvath | March 21, 2025View Berkshire Hathaway Bets on Constellation Brands—Should You?Buffett Trims Equities, But Still Keeps Buying This Stock By Jea Yu | April 1, 2025View Buffett Trims Equities, But Still Keeps Buying This Stock Warren Buffett Thinks This Country Could Be the Next Big Bet By Jea Yu | March 25, 2025View Warren Buffett Thinks This Country Could Be the Next Big Bet AMLX, ALEC, ABBV, ATHA, and COYA Company DescriptionsAbbVie NYSE:ABBV$186.58 -15.06 (-7.47%) Closing price 04/4/2025 03:59 PM EasternExtended Trading$186.80 +0.22 (+0.12%) As of 04/4/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.Alector NASDAQ:ALEC$1.02 -0.07 (-6.42%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.08 +0.05 (+5.39%) As of 04/4/2025 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Amylyx Pharmaceuticals NASDAQ:AMLX$3.43 -0.08 (-2.28%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$3.42 -0.01 (-0.15%) As of 04/4/2025 04:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Athira Pharma NASDAQ:ATHA$0.25 -0.01 (-3.85%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$0.25 +0.00 (+0.80%) As of 04/4/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Coya Therapeutics NASDAQ:COYA$5.45 -0.65 (-10.66%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$5.81 +0.36 (+6.68%) As of 04/4/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 03/31 - 04/04 Conagra Stock Could Thrive as Tariffs Hit Other Sectors Archer Aviation’s Africa Deal Could Boost ACHR Stock The Ecosystem Edge: Joby's Competitive Advantage Intel’s Big Bet on 18A: Will Lip-Bu Tan’s Vision Pay Off? Lamb Weston Stock Rises, Earnings Provide Calm Amidst Chaos Sportsman’s Warehouse Trading Volume Spike Signals Opportunity Spotify Stock Eyes Double-Digit Upside—Is Now the Time to Buy? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
